Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B

Amy D. Shapiro,Roshni Kulkarni,Margaret V. Ragni,Hervé Chambost,Johnny Mahlangu,Johannes Oldenburg,Beatrice Nolan,Margareth C. Ozelo,Meredith C. Foster,Annemieke Willemze,Christopher Barnowski,Nisha Jain,Bent Winding,Jennifer Dumont,Stefan Lethagen,Chris Barnes,K. John Pasi

Blood advances（2023）

引用 1|浏览41

暂无评分

摘要

•Pooled longitudinal efficacy and safety data for rFIXFc demonstrates sustained benefits in hemophilia B.•All evaluable target joints resolved during treatment, and no recurrence was reported in most (90%) baseline target joints during follow-up.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要